Research analysts at Roth Capital initiated coverage on shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $5.00 price target on the biotechnology company’s stock. Roth Capital’s price target points to a potential upside of 70.65% from the stock’s current price.

Several other research firms also recently weighed in on VKTX. ValuEngine downgraded shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Maxim Group restated a “buy” rating and set a $5.00 target price on shares of Viking Therapeutics in a report on Monday, September 11th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th.

Viking Therapeutics (NASDAQ:VKTX) opened at $2.93 on Tuesday. Viking Therapeutics has a twelve month low of $0.88 and a twelve month high of $3.24.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.03). sell-side analysts expect that Viking Therapeutics will post -0.86 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/viking-therapeutics-inc-vktx-now-covered-by-roth-capital/1720834.html.

Several institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in shares of Viking Therapeutics during the 3rd quarter worth about $108,000. Sphera Funds Management LTD. acquired a new stake in shares of Viking Therapeutics during the 3rd quarter worth about $554,000. Sabby Management LLC acquired a new stake in shares of Viking Therapeutics during the 2nd quarter worth about $525,000. Virtu KCG Holdings LLC acquired a new stake in shares of Viking Therapeutics during the 2nd quarter worth about $124,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Viking Therapeutics by 62.9% during the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 102,600 shares during the last quarter. 8.84% of the stock is currently owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.